IBRUTINIB COMBINED WITH BENDAMUSTINE/RITUXIMAB IN PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL): FIRST RESULTS FROM A RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY

被引：0

作者：

Cramer, P.

Chanan-Khan, A. ^{[1
]}

Demirkan, F. ^{[2
]}

Fraser, G. ^{[3
]}

Santucci Silva, R. ^{[4
]}

Pylypenko, H. ^{[5
]}

Grosicki, S. ^{[6
]}

Janssens, A. ^{[7
]}

Pristupa, A. ^{[8
]}

Mayer, J. ^{[9
]}

Dilhuydy, M. S. ^{[10
]}

Loscertales, J. ^{[11
]}

Bartlett, N. L. ^{[12
]}

Avigdor, A. ^{[13
,14
]}

Rule, S. ^{[15
]}

Sun, S. ^{[16
]}

Mahler, M. ^{[16
]}

Salman, M. ^{[16
]}

Howes, A. ^{[17
]}

Hallek, M. ^{[18
,19
]}

机构：

[1] Mayo Clin, IL-52621 Jacksonville, FL USA

[2] Dokuz Eylul Univ, Juravinski Canc Ctr, IL-69978 Izmir, Turkey

[3] McMaster Univ, Hemomed Oncol & Hematol, Hamilton PL6 8DH, ON, Canada

[4] IEP SAO LUCAS, Dept Hematol, Sao Paulo, Brazil

[5] Cherkassy Reg Oncol Ctr, Fac Publ Hlth, Dept Canc Prevent, Cherkassy, Ukraine

[6] Silesian Med Univ, D-50931 Katowice, Poland

[7] Univ Ziekenhuizen Leuven, D-50931 Leuven, Belgium

[8] Reg Clin Hosp, Dept Internal Med Hematol & Oncol, Ryazan, Russia

[9] Univ Hosp Brno, Brno, Czech Republic

[10] Hop Haut Leveque, Hematol Dept, IIS IP, Pessac, France

[11] Hosp Univ La Princesa, Sch Med, Siteman Canc Ctr, Madrid, Spain

[12] Washington Univ, Div Hematol & Bone Marrow Transplantat, St Louis, MO USA

[13] Chaim Sheba Med Ctr, Sackler Sch Med, Tel Hashomer, Israel

[14] Tel Aviv Univ, Dept Haematol, Tel Aviv, Israel

[15] Derriford Hosp, Plymouth, Devon, England

[16] Janssen Res & Dev LLC, Raritan, NJ USA

[17] Janssen Res & Dev, Dept Internal Med 1, High Wycombe, Bucks, England

[18] Univ Cologne, Ctr Integrated Oncol, Cologne, Germany

[19] Univ Cologne, Cologne, Germany

来源：

HAEMATOLOGICA | 2015年 / 100卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

LB218

引用

页码：55 / 56

页数：2

共 50 条

[1] Ibrutinib combined with bendamustine and rituximab (BR) in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): First results from a randomized, double-blind, placebo-controlled, phase III study
Chanan-Khan, Asher Alban Akmal
Cramer, Paula
Demirkan, Fatih
Fraser, Graeme
Silva, Rodrigo Santucci
Pylypenko, Halyna
Grosicki, Sebastian
Janssens, Ann
Pristupa, Alexander
Mayer, Jiri
Dilhuydy, Marie-Sarah
Loscertales, Javier
Bartlett, Nancy L.
Avigdor, Abraham
Rule, Simon
Sun, Steven
Mahler, Michelle
Salman, Mariya
Howes, Angela J.
Hallek, Michael J.
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (18)
[2] Ibrutinib combined with bendamustine/rituximab (BR) in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): safety analysis in the HELIOS trial
Cramer, Paula
Chanan-Khan, Asher
Fraser, Graeme
Demirkan, Fatih
Silva, Rodrigo Santucci
Pylypenko, Halyna
Grosicki, Sebastian
Janssens, Ann
Pristupa, Aleksander
Goy, Andre
Mayer, Jiri
Dilhuydy, Marie-Sarah
Loscertales, Javier
Barlett, Nancy
Avigdor, Abraham
Rule, Simon
Sun, Steven
Phelps, Charles
Mahler, Michelle
Salman, Masha
Howes, Angela
Hallek, Michael
LEUKEMIA & LYMPHOMA, 2015, 56 : 93 - 94
[3] Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study
Chanan-Khan, Asher
Cramer, Paula
Demirkan, Fatih
Fraser, Graeme
Silva, Rodrigo Santucci
Grosicki, Sebastian
Pristupa, Aleksander
Janssens, Ann
Mayer, Jiri
Bartlett, Nancy L.
Dilhuydy, Marie-Sarah
Pylypenko, Halyna
Loscertales, Javier
Avigdor, Abraham
Rule, Simon
Villa, Diego
Samoilova, Olga
Panagiotidis, Panagiots
Goy, Andre
Mato, Anthony
Pavlovsky, Miguel A.
Karlsson, Claes
Mahler, Michelle
Salman, Mariya
Sun, Steven
Phelps, Charles
Balasubramanian, Sriram
Howes, Angela
Hallek, Michael
Assouline, S.
Bence-Bruckler, I.
Buckstein, R.
Fraser, G.
Larratt, L.
Minuk, L.
Villa, D.
Angevine, A.
Bartlett, N.
Bixby, D.
Caimi, P.
Chanan-Khan, A.
Craig, M.
Forero-Torres, A.
Ganguly, S.
Goy, A.
Heffner, L.
Hermann, R.
Lansigan, F.
Leis, J.
Letzer, J.
LANCET ONCOLOGY, 2016, 17 (02): : 200 - 211
[4] Ibrutinib combined with bendamustine/rituximab (BR) in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): subgroup efficacy analyses from the HELIOS trial
Fraser, Graeme
Chanan-Khan, Asher
Cramer, Paula
Demirkan, Fatih
Silva, Rodrigo Santucci
Pylypenko, Halyna
Grosicki, Sebastian
Janssens, Ann
Pristupa, Aleksander
Goy, Andre
Mayer, Jiri
Dilhuydy, Marie-Sarah
Loscertales, Javier
Bartlett, Nancy
Avigdor, Abraham
Rule, Simon
Sun, Steven
Phelps, Charles
Mahler, Michelle
Salman, Masha
Howes, Angela
Hallek, Michael
LEUKEMIA & LYMPHOMA, 2015, 56 : 98 - 100
[5] Improvement of Quality of Response with Ibrutinib Plus Bendamustine/Rituximab Vs Placebo Plus Bendamustine/Rituximab for Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
Cramer, Paula
Chanan-Khan, Asher
Fraser, Graeme
Demirkan, Fatih
Silva, Rodrigo Santucci
Pylypenko, Halyna
Grosicki, Sebastian
Janssens, Ann
Goy, Andre
Mayer, Jiri
Dilhuydy, Marie Sarah
Loscertales, Javier
Bartlett, Nancy L.
Avigdor, Abraham
Rule, Simon
Sun, Steven
Phelps, Charles
Mahler, Michelle
Salman, Mariya
Schaffer, Michael
Balasubramanian, Sriram
Howes, Angela
Hallek, Michael
BLOOD, 2015, 126 (23)
[6] Ibrutinib in patients with autoimmune cytopenias and previously treated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) from the phase 3 RESONATETM study
Montillo, Marco
O'Brien, Susan
Tedeschi, Alessandra
Byrd, John
Dearden, Claire
Gill, Devinder
Brown, Jennifer
Barrientos, Jacqueline
Mulligan, Stephen
Furman, Richard
Cymbalista, Florence
Plascencia, Clara
Chang, Stephen
Hsu, Emily
James, Danelle
Hillmen, Peter
LEUKEMIA & LYMPHOMA, 2015, 56 : 150 - 151
[7] Updated results from the phase 3 HELIOS study of ibrutinib, bendamustine, and rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma
Fraser, G.
Cramer, P.
Demirkan, F.
Silva, R. Santucci
Grosicki, S.
Pristupa, A.
Janssens, A.
Mayer, J.
Bartlett, N. L.
Dilhuydy, M-S
Pylypenko, H.
Loscertales, J.
Avigdor, A.
Rule, S.
Villa, D.
Samoilova, O.
Panagiotidis, P.
Goy, A.
Pavlovsky, M. A.
Karlsson, C.
Hallek, M.
Mahler, M.
Salman, M.
Sun, S.
Phelps, C.
Balasubramanian, S.
Howes, A.
Chanan-Khan, A.
LEUKEMIA, 2019, 33 (04) : 969 - 980
[8] Updated results from the phase 3 HELIOS study of ibrutinib, bendamustine, and rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma
G. Fraser
P. Cramer
F. Demirkan
R. Santucci Silva
S. Grosicki
A. Pristupa
A. Janssens
J. Mayer
N. L. Bartlett
M.-S. Dilhuydy
H. Pylypenko
J. Loscertales
A. Avigdor
S. Rule
D. Villa
O. Samoilova
P. Panagiotidis
A. Goy
M. A. Pavlovsky
C. Karlsson
M. Hallek
M. Mahler
M. Salman
S. Sun
C. Phelps
S. Balasubramanian
A. Howes
A. Chanan-Khan
Leukemia, 2019, 33 : 969 - 980
[9] IBRUTINIB PLUS BENDAMUSTINE AND RITUXIMAB IN PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL): 2-YEAR FOLLOW-UP INCLUDING MRD FROM THE HELIOS STUDY
Fraser, G.
Cramer, P.
Demirkan, F.
Santucci Silva, R.
Grosicki, S.
Janssens, A.
Mayer, J.
Dilhuydy, M. S.
Pylypenko, H.
Loscertales, J.
Goy, A.
Avigdor, A.
Rule, S.
Phelps, C.
Mahler, M.
Salman, M.
Howes, A.
Hallek, M.
HAEMATOLOGICA, 2016, 101 : 150 - 151
[10] Impact of High Risk Prognostic Parameters and Addition of Ibrutinib to Bendamustine/Rituximab (BR) on Outcomes for Patients with Relapsed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) from the Phase 3 Double-Blind HELIOS Trial
Chanan-Khan, Asher
Cramer, Paula
Fraser, Graeme
Silva, Rodrigo Santucci
Grosicki, Sebastian
Pristupa, Aleksander
Dilhuydy, Marie Sarah
Goy, Andre
Mato, Anthony R.
Damle, Rajendra
Phelps, Charles
Mahler, Michelle
Salman, Mariya
Schaffer, Michael
Howes, Angela
Balasubramanian, Sriram
BLOOD, 2015, 126 (23)

← 1 2 3 4 5 →